The company projects 2026 revenues between $46.0bn and $47.5bn, with non-GAAP EPS ranging from $6.05 to $6.35.

Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy ...

The latest OXB agreement will help advance the company’s CAR-T therapies and provide a “reliable, scalable manufacturing ...

Bristol Myers Squibb (NYSE: BMY; BMS) beat analyst consensus forecasts by reporting higher than expected numbers for total revenue and its “growth” portfolio of drugs on which BMS is counting on for ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

Cellares, which last year became the first company to receive the FDA's new advanced manufacturing technology designation, ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | Bristol Myers Squibb added a big name to its executive roster with ...

Bristol Myers Squibb is leaning heavily on its newer key products, grouped into its growth portfolio category, to weather the storm it expects as it heads toward further declines within its legacy | ...

BMS Re, the reinsurance arm of independent re/insurance broker BMS Group, has appointed Tony Grippa as Chief Strategy Officer ...